• 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80: 82741.
  • 2
    Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 major cancers in 1990. Int J Cancer 1999;83: 1829.
  • 3
    Jin F, Devesa SS, Chow W-H, et al. Cancer incidence trends in urban Shanghai, 1972–94: an update. Int J Cancer 1999;83: 43540.
  • 4
    Taylor-Robinson SK, Foster BR, Arora S, et al. Increase in primary liver cancer in the U.K., 1979–94. Lancet 1997; 350: 11423.
  • 5
    Deuffic S, Poynard T, Buffat L, et al. Trends in primary liver cancer. Lancet 1998;351: 21415.
  • 6
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United Sates. N Engl J Med 1999;340: 74550.
  • 7
    Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, Vol VII. Lyon: IARC Scientific Publications No. 143, International Agency for Research on Cancer, 1997.
  • 8
    Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents, Vol V. Lyon: IARC Scientific Publications No. 88, International Agency for Research on Cancer, 1987.
  • 9
    Parkin DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents, Vol VI. Lyon: IARC Scientific Publications No. 120, International Agency for Research on Cancer, 1992.
  • 10
    WHO. International classification of diseases, 8th revision. Geneva: WHO, 1969.
  • 11
    WHO. International classification of diseases, 9th revision. Geneva: WHO, 1979.
  • 12
    NCI. SEER*Stat 3.0: SEER cancer incidence public-use database, 1973–97. 2000.
  • 13
    Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995;141: 3004.
  • 14
    Vatanasapt V, Martin N, Sriplung H, et al. Cancer incidence in Thailand, 1988–91. Cancer Epidemiol Biomarker Prev 1995;4: 47583.
  • 15
    Kullavanijaya P, Tangkijvanick P, Poovorawan Y. Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J Trop Med Public Health 1999;30: 96105.
  • 16
    London WT, McGlynn KA. Liver Cancer. In: SchottenfeldD, FraumeniJF, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996. 77293
  • 17
    Conio M, Demarquay J-F, De Luca L, et al. Endoscopic treatment of pancreatico-biliary malignancies. Crit Rev Oncol Hematol 2001;37: 127135.
  • 18
    Ahrendt SA, Pitt HA, Nakeeb A, et al. Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 1999;3: 357367.
  • 19
    La Vecchia C, Levi F, Lucchini F, et al. Worldwide patterns and trends in mortality from liver cirrhosis, 1955–90. Ann Epidemiol 1994;4: 4806.
  • 20
    El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160: 322730.
  • 21
    La Vecchia C, Lucchini F, Franceschi S, et al. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000;36: 90915.
  • 22
    Nomura A, Stemmermann GN, Chyou P-H, et al. Hepatitis B and C virus serologies among Japanese-Americans with hepatocellular carcinoma. J Infect Dis 1996;173: 14746.
  • 23
    WHO. Global status of hepatitis B immunization policy as of March, 2000. Available on the internet at
  • 24
    Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336: 18559.
  • 25
    Chen H-L, Chang M-H, Ni Y-H, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276: 9068.
  • 26
    WHO. Geographic pattern of hepatitis B prevalence, 1997. Available on the internet at
  • 27
    Qian G-S, Ross RK, Yu MC, et al, A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarker Prev 1994;3: 310.
  • 28
    McGlynn KA, Rosvold EA, Lustbader ED, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995;92: 23847.
  • 29
    Sun Z, Lu P, Gail MH, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999;30: 37983.
  • 30
    Yu S-Z, Chen G, Zhi X-L, et al. Primary liver cancer: natural toxins and prevention in China. J Toxicol Sci 1998;23(Suppl): 1437.
  • 31
    Hitzfield BC, Hoger SJ, Dietrick DR. Cyanobacterial toxins: removal during drinking water treatment, and human risk assessment. Environ Health Perspect 2000;108(Suppl): 11322.
  • 32
    Ling B. Health impairments arising from drinking water polluted with domestic sewage and excreta in China. Schriftenr Ver Wasser Boden Lufthyg 2000;105: 436.
  • 33
    Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355: 88791.
  • 34
    Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med 1999;197: 16S20S.
  • 35
    Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107: 2S9S.
  • 36
    WHO. Hepatitis C: global prevalence (update). Available on the internet at
  • 37
    Nishioka K, Watanake J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67: 42933.
  • 38
    Tomimatsu M, Ishiguro N, Taniai M, et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993;72: 6838.
  • 39
    Tanaka H, Hiyama T, Okubo Y, et al. Primary liver cancer incidence-rates related to hepatitis C-virus infection: a correlational study in Osaka, Japan. Cancer Causes Control 1994;5: 615.
  • 40
    Abe K, Edamoto Y, Park YN, et al. In situ detection of hepatitis B, C and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic areas. Hepatology 1998;28: 56872.
  • 41
    Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32(Suppl): 22537.
  • 42
    Colombo M, Rumi MG, Donato MF, et al. Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. Dig Dis Sci 1991;36: 11303.
  • 43
    Stroffolini T, Andreone P, Andriulli A, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998;29: 94452.
  • 44
    Brechot C, Jaffredo F, Lagorce D, et al. 1998. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998;29: 17383.
  • 45
    Tagger A, Donato F, Ribero ML, et al. 1999. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and synergism with hepatitis B virus and alcohol: Brescia HCC study. Int J Cancer 1999;81: 6959.
  • 46
    Nalpas B, Driss F, Pol S, et al. 1991. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991;12: 704.
  • 47
    Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2: 10046.
  • 48
    Caselmann WH, Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol 1996;24(Suppl): 616.
  • 49
    Petry W, Heintges T, Hensel F, et al. Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic. Z Gastroenterol 1997;35: 105967.
  • 50
    Peters M, Wellek S, Dienes HP, et al. Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Z Gastroenterol 1994;32: 114651.
  • 51
    Kaczynski J, Hansson G, Hermodsson S, et al. Minor role of hepatitis B and C virus infection in the etiology of hepatocellular carcinoma in a low-endemic area. Scan J Gastroenterol 1996;31: 80913.
  • 52
    Widell A, Verbann H, Wejstal R, et al. Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes. Scand J Infect Dis 2000;32: 14752.
  • 53
    Tao QM, Wang Y, Wang H, et al. 1992. Preliminary report on seroepidemiology of HCV and HBV infection in northern China. Chin Med J 1992;105: 20911.
  • 54
    Yuan J-M, Govindarajan S, Henderson BE, et al. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer 1996;74: 4913.
  • 55
    Cao K, Mizokami M, Orito E, et al. GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China. J Gastroenterol Hepatol 1998;13: 12418.
  • 56
    Yuan J-M, Govindarajan S, Ross RK, et al. Chronic infection with hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles County, California. Cancer 1999;86: 93643.
  • 57
    Yap I, Guan R, Kang JY, et al. Seroprevalence of antibodies to the hepatitis C virus in Singapore. Southeast Asian J Trop Med Public Health 1991;22: 5815.
  • 58
    Khin LW, Teo CJ, Guan R. Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore. Singapore Med J 1996;37: 4926.
  • 59
    Tangkijvanich P, Hirsch P, Theambooniers A, et al. Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J Gastroenterol 1999;34: 22733.
  • 60
    Di Bisceglie AM, Simpson LH, Lotze MT, et al. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994;19: 2226.
  • 61
    Hwang SJ, Tong MJ, Lai PP, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the USA. Gastroenterol Hepatol 1996;11: 94954.
  • 62
    Seeff LB, Miller RN, Rabkin CS, et al. Forty-five-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132: 10511.
  • 63
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus through infection in the United States, 1988 through 1994. N Engl J Med 1999;341: 55662.
  • 64
    Chiaramonte M, Stroffolini T, Caporaso N, et al. 1991. Hepatitis-C virus infection in Italy: a multicentric sero-epidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver). Ital J Gastroenterol 1991;23: 5558.
  • 65
    Chiba T, Matsuzaki R, Abei M, et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterology 1996;91: 1195203.
  • 66
    Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28: 268795.
  • 67
    Seeff LB. Natural history of hepatitis C. Am J Med 1999;107: 10S5S.
  • 68
    Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med 1999;107: 95S9S.
  • 69
    Seeff LB, Hollinger FE, Alter HJ, et al. Long-term mortality of transfusion-associated hepatitis (TAH). Hepatology 1998;28: 406A.
  • 70
    Poynard T, Bedossa P, Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997;349: 82532.
  • 71
    Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatol 2000;31: 51320.
  • 72
    Linnen J, Wages J, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271: 5058.
  • 73
    Nishizawa T, Okamoto H, Konishi K, et al. 1997. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophysic Research Comm 1997;241: 927.
  • 74
    Muller C, Pfeffel F, Peck-Radosavljevic M, et al. Prevalence of hepatitis G virus in patients with hepatocellular carcinoma. J Viral Hepat 1997;4: 4114.
  • 75
    Tagger A, Donato F, Ribero ML, et al. A case-control study on GB virus C/ Hepatitis C virus infection and hepatocellular carcinoma. Hepatology 1997;26: 16537.
  • 76
    Hollingsworth RC, Minton EJ, Fraser-Moodie C, et al. Hepatitis G infection: role in cryptogenic chronic liver disease and primary liver cell cancer in the U.K. Trent hepatitis C virus study group. J Viral Hepat 1998;5: 1659.
  • 77
    Lightfoot K, Skelton M, Kew MC, et al. Does hepatitis GB virus-C infection cause hepatocellular carcinoma in black Africans? Hepatology 1997;26: 7402.
  • 78
    Chiesa R, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarker Prev 2000;9: 2136.
  • 79
    Kato T, Mizokami M, Orito E, et al. High prevalence of TT virus infection in Japanese patients with liver diseases and in blood donors. J Hepatol 1999;31: 2217.
  • 80
    Shimizu T, Moriyama M, Matsumura H, et al. TT virus infection in patients with hepatocellular carcinoma associated with non-A–G hepatitis: histopathologic study. Nippon Rinsho 1999;57: 13816.
  • 81
    Tagger A, Donato F, Ribero ML, et al. A case-control study on the a novel DNA virus (TT virus) infection and hepatocellular carcinoma. Hepatology 1999;30: 2949.
  • 82
    Skelton M, Kew MC, Yu MC, et al. Transfusion-transmissible virus and hepatocellular carcinoma: a case-control study. J Viral Hepat 2000;7: 2304.
  • 83
    Yotsuyanagi H, Shintani Y, Moriya K, et al. 2000. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of the hepatitis B virus. J Infect Dis 2000;181: 19208.
  • 84
    Pineau P, Meddeb M, Raselli R, et al. Effect of TT virus infection on hepatocellular carcinoma development: results of a Euro-Asian survey. J Infect Dis 2000;181: 113842.
  • 85
    WHO. International classification of diseases for oncology, 2nd edition. Geneva: WHO, 1990.